These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24738180)

  • 1. [The world of galactose and glucose: pathogenesis and therapy of lysosomal diseases].
    Suzuki Y
    No To Hattatsu; 2014 Mar; 46(2):81-6. PubMed ID: 24738180
    [No Abstract]   [Full Text] [Related]  

  • 2. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal disorders associated with leukoencephalopathy.
    Renaud DL
    Semin Neurol; 2012 Feb; 32(1):51-4. PubMed ID: 22422206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a broad-spectrum retaining β-exo-galactosidase activity-based probe.
    Kuo CL; Su Q; van den Nieuwendijk AMCH; Beenakker TJM; Offen WA; Willems LI; Boot RG; Sarris AJ; Marques ARA; Codée JDC; van der Marel GA; Florea BI; Davies GJ; Overkleeft HS; Aerts JMFG
    Org Biomol Chem; 2023 Oct; 21(38):7813-7820. PubMed ID: 37724332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible use of CSF glycosphingolipids for the diagnosis and therapeutic monitoring of lysosomal storage diseases.
    Kaye EM; Ullman MD; Kolodny EH; Krivit W; Rischert JC
    Neurology; 1992 Dec; 42(12):2290-4. PubMed ID: 1461381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lyso-glycosphingolipids: presence and consequences.
    van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
    Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
    Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical chaperone therapy for GM1-gangliosidosis.
    Suzuki Y
    Cell Mol Life Sci; 2008 Feb; 65(3):351-3. PubMed ID: 18202827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders.
    Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P
    Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719
    [No Abstract]   [Full Text] [Related]  

  • 15. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for lysosomal storage disorders.
    Nakamura K; Hattori K; Endo F
    Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemical chaperone therapy for lysosomal storage diseases].
    Higaki K; Nanba E
    Seikagaku; 2015 Oct; 87(5):597-600. PubMed ID: 26638628
    [No Abstract]   [Full Text] [Related]  

  • 19. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
    Shayman JA; Larsen SD
    J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preface.
    Baker DC
    Adv Carbohydr Chem Biochem; 2016; 73():ix-x. PubMed ID: 27816109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.